Sionna Therapeutics, Inc.
SION Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.60
KIRA · Stoqly’s AI analyst, in plain words
- Sionna Therapeutics, Inc. lost $75.3M in fiscal 2025.
- Free cash flow was −$66.7M in fiscal 2025, — of revenue.
Market cap
$163M
P/E
—
Revenue
—
Net income
−$75.3M
Free cash flow
−$66.7M
Operating margin
—
Sionna Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$75.3M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sionna Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Sionna Therapeutics, Inc.
- CIK
- 0002036042
Sionna Therapeutics, Inc. · SION
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$61.7M | −$75.3M |
| Diluted EPS | −$15.99 | −$1.88 |
| Cash | ||
| Cash from operations | −$52.8M | −$66.3M |
| Capital expenditure | $0.0M | $0.4M |
| Free cash flow | −$52.8M | −$66.7M |
| Share count change | — | 935.6% |
| Debt and strength | ||
| Cash and short-term investments | $37.8M | $58.5M |
| Shareholders' equity | −$164M | $307M |
| Current ratio | 14.5x | 20.6x |
| Returns and quality | ||
| Return on equity | — | −105.2% |
| Return on tangible equity | — | −24.5% |
| Altman Z'' | −9.8 | 17.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$131M
6 insiders
Of sales under plans
76%
$99.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sionna Therapeutics, Inc. · SION
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.60 a share, the company is worth $163M.
Source: SEC EDGAR XBRL filings (CIK 0002036042). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.